EA
LGND icon

Ellsworth Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Ellsworth Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,565
Closed -$1.29M – 185
2025
Q4 		$1.29M Sell
6,565
-474
-7% -$91.1K 0.25% 92
2025
Q3 		$1.29M Sell
7,039
-288
-4% -$42.8K 0.28% 84
2025
Q2 		$833K Buy
7,327
+55
+0.8% +$5.88K 0.2% 101
2025
Q1 		$765K Buy
+7,272
New +$822K 0.2% 107

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Ellsworth Advisors's LGND Position: Q1 2026 in Review

Ellsworth Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 6,565 shares — an estimated $1.29M sold.

Ellsworth Advisors first reported a position in LGND in Q1 2025 and held it in 4 quarters. The position peaked at $1.29M in Q3 2025. 358 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Ellsworth Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ellsworth Advisors sold 6,565 Ligand Pharmaceuticals shares in Q1 2026, an estimated $1.29M.
  • Ellsworth Advisors first reported a position in Ligand Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Ellsworth Advisors's Ligand Pharmaceuticals position peaked at $1.29M in Q3 2025.
  • 358 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Ellsworth Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.